A Randomised, Double-blind, Multi-centre Placebo Controlled Trial of Dexmedetomidine for Patients With Agitation and Delirium in the Intensive Care Unit.
Phase of Trial: Phase II/III
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Agitation; Delirium
- Focus Therapeutic Use
- Acronyms DahLIA
- Sponsors Hospira
- 15 Mar 2016 Primary endpoint has been met. (Ventilator-free hours) as per the results published in the JAMA: the Journal of the American Medical Association
- 15 Mar 2016 Results published in the JAMA: the Journal of the American Medical Association
- 18 Jan 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.